JP2024534570A5 - - Google Patents
Info
- Publication number
- JP2024534570A5 JP2024534570A5 JP2024518365A JP2024518365A JP2024534570A5 JP 2024534570 A5 JP2024534570 A5 JP 2024534570A5 JP 2024518365 A JP2024518365 A JP 2024518365A JP 2024518365 A JP2024518365 A JP 2024518365A JP 2024534570 A5 JP2024534570 A5 JP 2024534570A5
- Authority
- JP
- Japan
- Prior art keywords
- ocular
- pharmaceutical suspension
- ophthalmic pharmaceutical
- inflammatory
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247174P | 2021-09-22 | 2021-09-22 | |
| US63/247,174 | 2021-09-22 | ||
| US202163251874P | 2021-10-04 | 2021-10-04 | |
| US63/251,874 | 2021-10-04 | ||
| PCT/US2022/076876 WO2023049809A1 (en) | 2021-09-22 | 2022-09-22 | Methods of treating ocular inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534570A JP2024534570A (ja) | 2024-09-20 |
| JP2024534570A5 true JP2024534570A5 (https=) | 2025-10-01 |
Family
ID=85571480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518365A Pending JP2024534570A (ja) | 2021-09-22 | 2022-09-22 | 眼炎症性疾患を処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12263160B2 (https=) |
| EP (1) | EP4405048A4 (https=) |
| JP (1) | JP2024534570A (https=) |
| AU (1) | AU2022353032A1 (https=) |
| CA (1) | CA3231766A1 (https=) |
| IL (1) | IL311534A (https=) |
| MX (1) | MX2024003580A (https=) |
| WO (1) | WO2023049809A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12102622B2 (en) * | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| US12564616B2 (en) * | 2022-05-20 | 2026-03-03 | Sol Gersh | Composition for respiratory diseases |
| CN116919958A (zh) * | 2023-07-05 | 2023-10-24 | 南方医科大学口腔医院 | 罗氟司特在骨缺损修复治疗中的应用 |
| WO2025024684A1 (en) * | 2023-07-25 | 2025-01-30 | Iolyx Therapeutics, Inc. | Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59410119D1 (de) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| SK122199A3 (en) * | 1997-03-18 | 2000-12-11 | Basf Ag | Methods and compositions for modulating responsiveness to corticosteroids |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| US20040242597A1 (en) * | 2001-09-19 | 2004-12-02 | Thomas Klein | Combination |
| PT1511516E (pt) | 2002-05-28 | 2009-02-20 | Nycomed Gmbh | Preparação farmacêutica para aplicação tópica |
| US20060263350A1 (en) | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| AU2005267706B2 (en) | 2004-08-02 | 2011-12-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
| US7576069B2 (en) | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| US8663694B2 (en) | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
| DK1906916T3 (da) | 2005-05-10 | 2009-01-19 | Alcon Inc | Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser |
| BRPI0609227A2 (pt) | 2005-05-10 | 2010-03-09 | Alcon Inc | composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos |
| EP1889620A4 (en) * | 2005-06-09 | 2008-12-10 | Santen Pharmaceutical Co Ltd | EYE DROPS CONTAINING ROFLUMILAST |
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| CA2712017C (en) | 2008-01-18 | 2016-08-09 | Oxagen Limited | Compounds having crth2 antagonist activity |
| RS54413B1 (sr) | 2008-08-22 | 2016-04-28 | Sanofi | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita |
| EP2506878A2 (en) | 2009-12-03 | 2012-10-10 | Lupin Limited | Process for preparing pharmaceutical ophthalmic compositions |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| WO2015132708A1 (en) | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| TW201729810A (zh) | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| MX2021003633A (es) | 2018-10-16 | 2021-05-27 | Res Triangle Inst | Dispositivo de depósito biodegradable subcutáneo. |
| EP4061332A4 (en) | 2019-11-24 | 2023-11-29 | Sol-Gel Technologies Ltd. | TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR |
| CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
| US12102622B2 (en) * | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
-
2022
- 2022-09-22 WO PCT/US2022/076876 patent/WO2023049809A1/en not_active Ceased
- 2022-09-22 EP EP22873866.2A patent/EP4405048A4/en active Pending
- 2022-09-22 MX MX2024003580A patent/MX2024003580A/es unknown
- 2022-09-22 AU AU2022353032A patent/AU2022353032A1/en active Pending
- 2022-09-22 US US17/950,802 patent/US12263160B2/en active Active
- 2022-09-22 IL IL311534A patent/IL311534A/en unknown
- 2022-09-22 JP JP2024518365A patent/JP2024534570A/ja active Pending
- 2022-09-22 CA CA3231766A patent/CA3231766A1/en active Pending
-
2025
- 2025-03-06 US US19/072,354 patent/US20250195489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534570A5 (https=) | ||
| Casson | Medical therapy for glaucoma: A review | |
| AU2011284589B2 (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| Krueger et al. | Clinical analysis of excimer laser photorefractive keratectomy using a multiple zone technique for severe myopia | |
| JP2016538292A (ja) | 持続的薬物送達インプラントによる眼の状態の治療の方法 | |
| JP2024534570A (ja) | 眼炎症性疾患を処置する方法 | |
| CN109996814A (zh) | 多激酶抑制剂及在眼部纤维化中的用途 | |
| JP6116714B2 (ja) | 眼科炎症疾患治療用点眼剤組成物及びその製造方法 | |
| Morgado et al. | Comparative study of mydriasis in cataract surgery: topical versus Mydriasert versus intracameral mydriasis in cataract surgery | |
| Partamian | Treatment of a cyclodialysis cleft with argon laser photocoagulation in a patient with a shallow anterior chamber | |
| Ang et al. | A case series of bee sting keratopathy with different outcomes in Malaysia | |
| Bikbov et al. | Current opportunities for the prevention of excessive scarring after glaucoma surgery using antimetabolites | |
| Bertens et al. | Combination drug delivery approaches in ophthalmology | |
| Suleiman et al. | New techniques of sinus trabeculectomy with prolonged hypotensive effect | |
| RU2857003C1 (ru) | Способ хирургического лечения стойкой гипотонии глаза после антиглаукомной фильтрующей операции с применением аутологичной теноновой оболочки | |
| CN117652454B (zh) | 一种闭角型青光眼动物模型的建立方法 | |
| RU2844725C1 (ru) | Способ хирургического лечения диабетического макулярного отека | |
| RU2303457C1 (ru) | Способ проведения энзимотерапии | |
| WO2002078713A1 (fr) | Medicaments contre les affections retiniennes et choroidiennes contenant des steroides comme principe actif | |
| RU2430707C1 (ru) | Способ лечения больных с глаукомной оптической нейропатией | |
| Galloway et al. | Drugs and the Eye | |
| Tian et al. | Ophthalmic Drugs | |
| RU2726457C1 (ru) | Комбинированная антиглаукоматозная операция с экстракцией хрусталика | |
| Arora et al. | Ophthalmic drug delivery system—A concise review on its conventional and novel approaches | |
| RU2688960C1 (ru) | Способ комбинированного хирургического лечения вторичной глаукомы, вызванной эмульгированием силикона |